Patents by Inventor Greg Thomas

Greg Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080125453
    Abstract: Compositions of tannate salts of phenylephrine, pyrilamine, and dextromethorphan produced by a method that allows for the in-situ conversions and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving salts of phenylephrine, pyrilamine, and dextromethorphan in a solvent and mixing with a dispersing agent and tannic acid to generate tannate salts. The tannate salts may be further processed without further purification or isolation to single dosage forms, such as tablets and suspension.
    Type: Application
    Filed: February 8, 2008
    Publication date: May 29, 2008
    Applicant: TIBER LABORATORIES, LLC
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 7273623
    Abstract: An active pharmaceutical ingredient is combined with tannic acid to form a tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then blended with pharmaceutically acceptable excipients to form a granulate which is processed into a tablet or capsule to generate a therapeutic solid dosage form.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: September 25, 2007
    Assignee: Kiel Laboratories, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 7094429
    Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: August 22, 2006
    Assignee: Kiel Laboratories, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20050280630
    Abstract: A computerized interactor system uses physical, three-dimensional objects as metaphors for input of user intent to a computer system. When one or more interactors are engaged with a detection field, the detection field reads an identifier associated with the object and communicates the identifier to a computer system. The computer system determines the meaning of the interactor based upon its identifier and upon a semantic context in which the computer system is operating.
    Type: Application
    Filed: August 25, 2005
    Publication date: December 22, 2005
    Inventors: Emily Weil, Greg Thomas, S. Mountford, Thomas Dougherty, Daniel Cummings
  • Patent number: 6952196
    Abstract: A computerized interactor system uses physical, three-dimensional objects as metaphors for input of user intent to a computer system. When one or more interactors are engaged with a detection field, the detection field reads an identifier associated with the object and communicates the identifier to a computer system. The computer system determines the meaning of the interactor based upon its identifier and upon a semantic context in which the computer system is operating. One specific embodiment of the present invention is a bead interactor system that is a user playable sound and light show system. When an interactor bead is positioned within the detection space of the bead interactor system, a sound sequence begins and continues to play unaltered until the bead interactor is removed or other bead interactors are positioned within or removed from the detection space.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: October 4, 2005
    Assignee: Vulcan Patents LLC
    Inventors: Emily Weil, Greg Thomas, S. Joy Mountford, Thomas J. Dougherty, Daniel E. Cummings
  • Patent number: 6869618
    Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: March 22, 2005
    Assignee: Kiel Laboratories, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20040234593
    Abstract: A therapeutic composition comprises diphenhydramine tannate in the substantial absence of other active ingredients. The composition has utility in providing symptomatic relief of sneezing, itchy, watery eyes, itchy nose or throat and runny nose due to hay fever (allergic rhinitis) or other respiratory allergies.
    Type: Application
    Filed: March 5, 2004
    Publication date: November 25, 2004
    Inventors: Jeffrey S Kiel, H Greg Thomas, Narasimhan Mani
  • Publication number: 20040192616
    Abstract: The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.
    Type: Application
    Filed: March 22, 2004
    Publication date: September 30, 2004
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20040192618
    Abstract: The present invention relates to pharmaceutical compositions of gabapentin tannate, processes for production of those compositions and methods of use of those compositions. The present invention provides a novel process for preparation of the tannate salt of gabapentin in liquid or semi-solid dosage form for human and veterinary pharmaceutical use. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.
    Type: Application
    Filed: March 22, 2004
    Publication date: September 30, 2004
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20040192617
    Abstract: The present invention provides a novel process for preparation of the tannate salt of gabapentin for human and veterinary pharmaceutical use. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. However, the prior art neither discloses nor suggests the preparation of gabapentin tannate. The process for preparing gabapentin tannate includes the mixing of gabapentin and tannic acid together in the presence of one or more solvents. The method may further include the step of selecting the one or more solvents from a group consisting of purified water, ethanol, glycerin, propylene glycol, diethylether, methylene chloride, acetone, isopropyl alcohol and mixtures thereof. The process may also include the steps of isolating and purifying the tannate salt. This may be accomplished by filtration, drying, centrifugation and lyophilization. The process may utilize either natural or synthetic tannic acid.
    Type: Application
    Filed: March 22, 2004
    Publication date: September 30, 2004
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20040132827
    Abstract: Compositions of tannate salts of phenylephrine, pyrilamine, and dextromethorphan produced by a method that allows for the in-situ conversion and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving salts of phenylephrine, pyrilamine, and dextromethorphan in a solvent and mixing with a dispersing agent and tannic acid to generate tannate salts. The tannate salts may be further processed without further purification or isolation to single dosage forms, such as tablets and suspension.
    Type: Application
    Filed: August 22, 2003
    Publication date: July 8, 2004
    Applicant: PediaMed Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20040008182
    Abstract: A computerized interactor system uses physical, three-dimensional objects as metaphors for input of user intent to a computer system. When one or more interactors are engaged with a detection field, the detection field reads an identifier associated with the object and communicates the identifier to a computer system. The computer system determines the meaning of the interactor based upon its identifier and upon a semantic context in which the computer system is operating. One specific embodiment of the present invention is a bead interactor system that is a user playable sound and light show system. When an interactor bead is positioned within the detection space of the bead interactor system, a sound sequence begins and continues to play unaltered until the bead interactor is removed or other bead interactors are positioned within or removed from the detection space.
    Type: Application
    Filed: March 27, 2003
    Publication date: January 15, 2004
    Applicant: Interval Research Corporation
    Inventors: Emily Weil, Greg Thomas, S. Joy Mountford, Thomas J. Dougherty, Daniel E. Cummings
  • Publication number: 20030225103
    Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells.
    Type: Application
    Filed: March 25, 2003
    Publication date: December 4, 2003
    Applicant: DMI BioSciences, Inc.
    Inventors: David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas
  • Publication number: 20030083354
    Abstract: Compositions of tannate salts of phenylephrine and pyrilamine produced by a method that allows for the in-situ conversion and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving a salts of phenylephrine and pyrilamine in a solvent and mixing with a dispersing agent and tannic acid to generate tannate salts. The tannate salts may be further processed to single dosage forms, such as tablets and suspensions.
    Type: Application
    Filed: October 26, 2001
    Publication date: May 1, 2003
    Applicant: PediaMed Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Patent number: 6556184
    Abstract: A computerized interactor system uses physical, three-dimensional objects as metaphors for input of user intent to a computer system. When one or more interactors are engaged with a detection field, the detection field reads an identifier associated with the object and communicates the identifier to a computer system. The computer system determines the meaning of the interactor based upon its identifier and upon a semantic context in which the computer system is operating. One specific embodiment of the present invention is a bead interactor system that is a user playable sound and light show system. When an interactor bead is positioned within the detection space of the bead interactor system, a sound sequence begins and continues to play unaltered until the bead interactor is removed or other bead interactors are positioned within or removed from the detection space.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: April 29, 2003
    Assignee: Interval Research Corp
    Inventors: Emily Weil, Greg Thomas, S. Joy Mountford, Thomas J. Dougherty, Daniel E. Cummings
  • Patent number: 6555543
    Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R1 and R2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: April 29, 2003
    Assignee: DMI BioSciences, Inc.
    Inventors: David Bar-Or, C. Gerald Curtis, Nagaraja K. R. Rao, Greg Thomas
  • Publication number: 20030077321
    Abstract: An active pharmaceutical ingredient is combined with tannic acid to form a tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then blended with pharmaceutically acceptable excipients to form a granulate which is processed into a tablet or capsule to generate a therapeutic solid dosage form.
    Type: Application
    Filed: October 10, 2002
    Publication date: April 24, 2003
    Applicant: KIEL LABORATORIES, INC.
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20030050252
    Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.
    Type: Application
    Filed: April 9, 2002
    Publication date: March 13, 2003
    Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
  • Publication number: 20020052381
    Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 2, 2002
    Inventors: David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas
  • Publication number: 20020033801
    Abstract: A computerized interactor system uses physical, three-dimensional objects as metaphors for input of user intent to a computer system. When one or more interactors are engaged with a detection field, the detection field reads an identifier associated with the object and communicates the identifier to a computer system. The computer system determines the meaning of the interactor based upon its identifier and upon a semantic context in which the computer system is operating. One specific embodiment of the present invention is a bead interactor system that is a user playable sound and light show system. When an interactor bead is positioned within the detection space of the bead interactor system, a sound sequence begins and continues to play unaltered until the bead interactor is removed or other bead interactors are positioned within or removed from the detection space.
    Type: Application
    Filed: November 16, 2001
    Publication date: March 21, 2002
    Inventors: Emily Weil, Greg Thomas, S. Joy Mountford, Thomas J. Dougherty, Daniel E. Cummings